Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 19/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5035229 | 0.91 | ALDH1A1 (0.38) | P2RX3ALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL14285915 | 0.85 | ALDH1A1 (0.38) | P2RX3ALDH1A1GAAMAPTHPGD | |
| SCHEMBL14626454 | 0.83 | ALDH1A1 (0.37) | P2RX3ALDH1A1GAAMAPTHPGD | |
| SCHEMBL5028711 | 0.79 | POLB (0.32) | P2RX3ALDH1A1 | |
| SCHEMBL14285916 | 0.78 | ALDH1A1 (0.40) | P2RX3ALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL14626457 | 0.77 | ALDH1A1 (0.39) | P2RX3ALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL5030915 | 0.76 | GPR139 (0.30) | — | |
| SCHEMBL5030916 | 0.75 | MEN1 (0.32) | ALDH1A1GAAMAPT | |
| SCHEMBL5030933 | 0.75 | — | — | |
| SCHEMBL5035241 | 0.74 | MAPT (0.35) | ALDH1A1GAAMAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | AJINOMOTO CO., INC. (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | AJINOMOTO CO., INC. (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | AJINOMOTO CO., INC. (JP) | 2008-01-24 | — | — | US | disclosed |
| WO-2007010015-A1 | PROCESSES FOR PREPARING PYRAZOLE-O-GLYCOSIDE DERIVATIVES AND NOVEL INTERMEDIATES OF SAID PROCESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | CYP4B1, CYP1B1, CYP11B1 | P2RX3 713/4885ALDH1A1 622/4885GAA 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.